Hip-related toxicity after prostate radiotherapy: Treatment related or coincidental?

To evaluate the incidence and predictors of hip toxicity postradiotherapy for localized prostate cancer.

4067 prostate cancer patients were treated with external beam radiotherapy (EBRT; n=2569; 63%) or brachytherapy with or without supplemental EBRT (n=1508; 27%). 43% (n=1738) were treated with neo-adjuvant and concurrent ADT and 57% (n=2329) with radiotherapy alone. Hip toxicity was defined as moderate or severe pain upon ambulation with or without the need for hip-revision surgery. Median follow-up was 7years (range, 3-21years).

One hundred twenty-one (2.7%) patients developed moderate-to-severe hip pain after radiotherapy affecting ambulation. Of these, 73 (60%) required hip replacement secondary to persistent hip pain. Among patients with baseline degenerative joint disease (DJD) changes on scans, 10-year incidence of hip-related toxicity was 11% versus 3% for those without such changes (P<.001). The only variables on multivariate analysis associated with hip-related toxicity post-radiotherapy were baseline DJD on imaging (P<.0001) and prolonged ADT for salvage therapy (P<.0001).

Prostate EBRT or brachytherapy is associated with low incidence of long-term hip-related toxicity. The only variables identified associated with hip toxicity posttherapy was the presence of baseline DJD and prolonged salvage ADT posttreatment for patients developing recurrence.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2016 Oct 15 [Epub ahead of print]

Michael J Zelefsky, Marisa A Kollmeier, Elan Gorshein, Xin Pei, Marina Torres, Sean McBride, Laura Happersett, Gil'ad N Cohen, Yoshiya Yamada

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA. Electronic address: ., Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA., Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, USA.


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.